首页> 外文OA文献 >Identification and evaluation of inhibitors targeting the HIV-1 integrase-LEDGF/p75 interaction
【2h】

Identification and evaluation of inhibitors targeting the HIV-1 integrase-LEDGF/p75 interaction

机译:鉴定和评估靶向HIV-1整合酶-LEDGF / p75相互作用的抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The human immunodeficiency virus type 1 (HIV-1) integrase (IN) facilitates the irreversible integration of the viral chromosome into the host DNA in a two-step reaction process consisting of 3’ end processing and strand transfer. The pre-integration complex (PIC) is a nucleoprotein complex consisting of HIV-1 IN, reverse transcriptase, matrix, nucleocapsid, viral protein R (Vpr) and various cellular host proteins. The dominant host protein that forms part of the PIC is known as lens epithelium derived growth factor (LEDGF/p75) that is ubiquitously expressed in the nucleus. The integration of HIV-1 into chromatinised template is stimulated by LEDGF/p75, while LEDGF/p75 stabilizes HIV-1 IN subunit-subunit interactions and promotes HIV-1 IN tetramerisation. This study aimed to identify and evaluate potential inhibitors of the HIV-1 IN-LEDGF/p75 interaction. A compound library (NCC-202) comprised of 281 compounds obtained from the NIH clinical collection was screened through an HIV-1 IN-LEDGF/p75 molecular model prepared on Accelrys Discovery StudioTM 3.1. Recombinant HIV-1 IN and LEDGF/p75 were expressed in bacterial cells and purified by nickel affinity and cation exchange chromatography, and used to establish an AlphaScreen assay for compound screening. A total of twelve compounds were identified as possible HIV-1 IN-LEDGF/p75 inhibitors. Biochemical screening using an AlphaScreen assay was used and a total of six of the twelve inhibitors displaying inhibition above 50 % were identified. The best compound with an IC50 of 1.97 μM was identified as lovastatin. Lovastatin was found to have an EC50 of 6.54 μM in the antiviral assay but activity was likely attributed to cytotoxicity with a CC50 of 5.31 μM. Based on information from structurally similar statins, we hypothesised that a closed lactone ring in combination with a methyl group on the naphthalene structure elicited the likely inhibitory profile and that the lactone ring induced a large part of the cytotoxic effect of the compounds screened. Overall, we identified statins as potential inhibitors of the HIV-1 IN-LEDGF/p75 interaction, however the overlap of toxicity with antiviral effects renders statins in their current form unsuitable for antiretroviral treatment.
机译:人类免疫缺陷病毒1型(HIV-1)整合酶(IN)促进病毒染色体不可逆地整合到宿主DNA中,过程分为两步,包括3'末端加工和链转移。整合前复合物(PIC)是一种核蛋白复合物,由HIV-1 IN,逆转录酶,基质,核衣壳,病毒蛋白R(Vpr)和各种细胞宿主蛋白组成。形成PIC的主要宿主蛋白称为晶状体上皮衍生生长因子(LEDGF / p75),其在细胞核中普遍表达。 LEDGF / p75刺激HIV-1整合入染色模板中,而LEDGF / p75稳定HIV-1 IN亚基-亚基相互作用并促进HIV-1 IN四聚化。这项研究旨在鉴定和评估HIV-1 IN-LEDGF / p75相互作用的潜在抑制剂。通过在Accelrys Discovery StudioTM 3.1上制备的HIV-1 IN-LEDGF / p75分子模型筛选包含281种从NIH临床样本中获得的化合物的化合物库(NCC-202)。重组HIV-1 IN和LEDGF / p75在细菌细胞中表达,并通过镍亲和力和阳离子交换色谱法纯化,并用于建立用于化合物筛选的AlphaScreen测定法。总共鉴定出十二种化合物可能是HIV-1 IN-LEDGF / p75抑制剂。使用了使用AlphaScreen分析的生化筛选,在显示出抑制率超过50%的十二种抑制剂中,总共鉴定出六种。 IC50为1.97μM的最佳化合物被鉴定为洛伐他汀。在抗病毒测定中,洛伐他汀的EC50为6.54μM,但活性可能归因于细胞毒性,CC50为5.31μM。基于结构相似的他汀类药物的信息,我们假设封闭的内酯环与萘结构上的甲基结合会引起可能的抑制作用,并且内酯环诱导了所筛选化合物的大部分细胞毒性作用。总体而言,我们将他汀类药物确定为HIV-1 IN-LEDGF / p75相互作用的潜在抑制剂,但是毒性与抗病毒作用的重叠使得他汀类药物目前的形式不适合抗逆转录病毒治疗。

著录项

  • 作者

    Harrison Angela Theresa;

  • 作者单位
  • 年度 2014
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号